<DOC>
	<DOCNO>NCT01399684</DOCNO>
	<brief_summary>This Phase II , multicenter , randomize , double-blind , placebo-controlled trial design estimate efficacy MEGF0444A treatment disease progression , combine oxaliplatin + folinic acid + 5-Fluorouracil ( mFOLFOX-6 ) + bevacizumab therapy participant metastatic colorectal cancer ( CRC ) .</brief_summary>
	<brief_title>A Study Evaluating Efficacy Safety MEGF0444A Dosed Progression Combination With Bevacizumab mFOLFOX-6 Participants With Previously Untreated Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Histologically cytologically confirm CRC amenable potentially curative resection least one measurable metastatic lesion , define RECIST v1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate hematologic end organ function For female participant childbearing potential male participant partner childbearing potential , agreement use highly effective form contraception continue use 6 month last dose study treatment Negative serum pregnancy test within 7 day prior start study treatment premenopausal woman woman less ( &lt; ) 2 year onset menopause Diseasespecific exclusion Any prior systemic therapy ( include chemotherapy , antibody therapy , tyrosine kinase inhibitor , radiotherapy , immunotherapy , hormonal therapy investigational therapy ) Day 1 Cycle 1 treatment CRC General Medical Exclusions Malignancies CRC within 5 year prior randomization , except negligible risk metastasis death Radiotherapy site reason within 28 day prior Day 1 Cycle 1 Clinically detectable thirdspace fluid collection control drainage procedure prior study entry Treatment investigational agent participation another clinical trial therapeutic intent within 28 day prior Day 1 Cycle 1 Lactating woman Clinically suspect confirmed central nervous system ( CNS ) metastases carcinomatous meningitis Active infection require IV antibiotic Active autoimmune disease control nonsteroidal antiinflammatory drug , inhale corticosteroid , equivalent less equal ( &lt; /= ) 10 milligram per day ( mg/day ) prednisone Known clinically significant liver disease , include active viral , alcoholic , hepatitis , cirrhosis Sensory peripheral neuropathy great equal ( &gt; /= ) Grade 2 BevacizumabSpecific Exclusions Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use bevacizumab investigational drug may affect interpretation result render participant high risk treatment complication Inadequately control hypertension Prior history hypertensive crisis hypertensive encephalopathy New York Heart Association ( NYHA ) Class II great congestive heart failure ( CHF ) History myocardial infarction unstable angina within 6 month prior Day 1 History stroke transient ischemic attack ( TIA ) within 6 month prior Day 1 Significant vascular disease within 6 month prior Day 1 Evidence bleed diathesis significant coagulopathy Current recent ( within 10 day first dose study treatment ) use aspirin treatment dipyramidole , ticlopidine , clopidogrel , cilostazol Current recent ( within 10 day prior study treatment start ) use fulldose oral parenteral anticoagulant thrombolytic agent therapeutic purpose Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 1 , anticipation need major surgical procedure course study Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior Day 1 History abdominal tracheooesophageal fistula gastrointestinal ( GI ) perforation within 6 month prior Day 1 Clinical sign symptom GI obstruction requirement routine parenteral hydration , parenteral nutrition , tube feed Evidence abdominal free air explain paracentesis recent surgical procedure Serious , nonhealing dehisce wound , active ulcer , untreated bone fracture 5FluorouracilSpecific Exclusion Known dihydropyrimidine dehydrogenase deficiency thymidylate synthase gene polymorphism predispose participant 5fluorouracil toxicity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>